{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+IV+%28Human%29%2C+10%25+Caprylate%2FChromatography+Purified",
    "query": {
      "intervention": "Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+IV+%28Human%29%2C+10%25+Caprylate%2FChromatography+Purified&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T18:15:19.959Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00220740",
      "title": "Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"
      ],
      "interventions": [
        {
          "name": "Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2004-04",
      "completion_date": "2006-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-23",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220740"
    },
    {
      "nct_id": "NCT02915263",
      "title": "The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Complications",
        "Diabetes Mellitus",
        "Diabetic Neuropathies"
      ],
      "interventions": [
        {
          "name": "IGIV-C",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 13,
      "start_date": "2017-09-11",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2024-05-07",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915263"
    },
    {
      "nct_id": "NCT03401073",
      "title": "IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Idiopathic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-01",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401073"
    },
    {
      "nct_id": "NCT02473952",
      "title": "A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myasthenia Gravis, Generalized"
      ],
      "interventions": [
        {
          "name": "IGIV-C",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 62,
      "start_date": "2015-08",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02473952"
    },
    {
      "nct_id": "NCT00220727",
      "title": "Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Purpura, Thrombocytopenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 8,
      "start_date": "2003-07",
      "completion_date": "2003-10",
      "has_results": true,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220727"
    },
    {
      "nct_id": "NCT00389324",
      "title": "A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunologic Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "13 Years to 75 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-11",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2015-04-20",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 6,
      "location_summary": "Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389324"
    },
    {
      "nct_id": "NCT04480424",
      "title": "Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "GAMUNEX-C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Medical Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-09-17",
      "completion_date": "2021-10-25",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 18,
      "location_summary": "Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480424"
    },
    {
      "nct_id": "NCT02604810",
      "title": "Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "IGIV-C 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IGSC 20%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-01",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02604810"
    },
    {
      "nct_id": "NCT00220779",
      "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 128,
      "start_date": "2002-12",
      "completion_date": "2005-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220779"
    },
    {
      "nct_id": "NCT01465958",
      "title": "Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "GAMUNEX-C",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 12,
      "start_date": "2011-11",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-03-13",
      "last_synced_at": "2026-10-10T18:15:19.959Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Centennial, Colorado • Hollywood, Florida + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465958"
    }
  ]
}